Renal cancer 1st line randomised PII KMUA3B #ESMO25 with lenavatinib/pembro as the control (hard to beat with RR>80%). Len/pem/belzutifan showed good PFS (HR0.45) ✅ which may lead to a positive RIII (LS12) which is ongoing. TIGIT 🛑 & LAG3 🛑 were disappointing again OncoAlert
🌍 #VHIO participó en el Exchange Program for Clinical Trials de #EUnetCCC, organizado por Claudia Valverde.
En la sesión, Samira Serhir Sgheiri y Laia presentaron la organización de ensayos clínicos y herramientas para optimizar el reclutamiento.